Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:Clozaril
|
| gptkbp:activities |
dopamine receptor antagonist
|
| gptkbp:approves |
gptkb:1990
gptkb:FDA |
| gptkbp:brand |
gptkb:Clozaril
Faza Clo |
| gptkbp:clinical_trial |
Phase IV
Phase II Phase III |
| gptkbp:contraindication |
gptkb:hospital
bone marrow suppression myocarditis severe CNS depression |
| gptkbp:developed_by |
gptkb:Sandoz
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
clozapine
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P1 A2 inhibitors |
| gptkbp:is_available_on |
gptkb:tablet
orally disintegrating tablet |
| gptkbp:is_monitored_by |
white blood cell count
absolute neutrophil count |
| gptkbp:is_used_for |
treatment of schizophrenia
|
| gptkbp:lifespan |
12 hours
|
| gptkbp:manager |
oral
intramuscular |
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:provides_information_on |
gptkb:World_Health_Organization_(WHO)
National Institute for Health and Care Excellence (NICE) American Psychiatric Association (APA) Canadian Psychiatric Association (CPA) Royal Australian and New Zealand College of Psychiatrists (RANZCP) |
| gptkbp:research_areas |
bipolar disorder
neurodevelopmental disorders psychotic disorders suicidal behavior treatment-resistant schizophrenia |
| gptkbp:side_effect |
metabolic syndrome
seizures cardiovascular issues weight gain sedation endocrine disorders gastrointestinal issues neuroleptic malignant syndrome agranulocytosis hypersalivation |